Empowered Funds LLC Purchases Shares of 23,171 Medpace Holdings, Inc. $MEDP

Empowered Funds LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 23,171 shares of the company’s stock, valued at approximately $12,271,000. Empowered Funds LLC owned about 0.08% of Medpace as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. NewEdge Advisors LLC boosted its stake in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Medpace in the second quarter worth about $296,000. Finally, M&T Bank Corp lifted its stake in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the transaction, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 133,821 shares of company stock worth $81,748,135 over the last three months. 20.50% of the stock is owned by corporate insiders.

Medpace Price Performance

MEDP stock opened at $600.65 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a 50-day moving average of $565.33 and a 200 day moving average of $494.55. The company has a market cap of $16.76 billion, a P/E ratio of 35.21, a PEG ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the topic of several recent research reports. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.